Home| About us| Widget| login/register| For authors| For reviewers |Submit a paper
(close)

(Ctrl-click to select multiple journals)


How should we address you?

Your email address


 Yes, sign up now
 Sign up for general news too

Privacy Statement
 
 
 

Drug Target Insights

Synopsis: An open access, peer reviewed electronic journal that covers drug treatment targets.


Indexing: 6 major databases. Pubmed indexing for NIH-funded research.

Processing time: Decision in 2 weeks for 90% of papers.

Visibility: Most popular article read 1400+ times.

RSS

NEWS

TWITTER
View factor
for journal
80130


About this journal

ISSN: 1177-3928



Aims and scope:

Drug Target Insights covers current developments in all areas of the field of clinical therapeutics. The journal has two specific areas of focus:

  • On molecular drug targets, including disease-specific proteins, receptors, enzymes, and genes.
  • The journal seeks to elucidate the impact of new therapeutic agents on patient acceptability, preference, satisfaction and quality of life.

Drug Target Insights seeks to be the most up-to-date journal for those who need to be informed of the latest and most important developments in the field. The journal seeks to be the most reliable and up-to-date journal in this field by offering rapid and credible pre-production submission processing to authors. By publishing in open-access format, authors are able to communicate with the widest possible group of readers.

Editorial standards and procedures:

Submissions, excluding editorials, letters to the editor and dedications, will be peer reviewed by two reviewers.  Reviewers are required to provide fair, balanced and constructive reports.  

Under our Fairness in Peer Review Policy authors may appeal against reviewers' recommendations which are ill-founded, unobjective or unfair.  Appeals are considered by the Editor in Chief or Associate Editor.

Papers are not sent to peer reviewers following submission of a revised manuscript. Editorial decisions on re-submitted papers are based on the author's response to the initial peer review report.

Indexing:

This journal is indexed by the following services:

  • Embase
  • Google Scholar
  • CAS
  • DOAJ
  • OAIster

SPARC Europe Seal award winner:

This journal has been awarded a SPARC Europe Seal. The Seal is an initiative of SPARC Europe (Scholarly Publishing and Academic Resources Coalition) and the Directory of Open Access Journals (DOAJ) which is awarded to journals applying a Creative Commons CC-BY copyright license and that make journal metadata accessible to DOAJ.  

Amongst other important services DOAJ makes metadata OAI-compliant.  This in turn enhances the visibility of papers and allows OAI-harvesters to include the details of journal articles in their services. We encourage readers to make use of this valuable resource.  The DOAJ search page is available here.

National Institutes of Health Public Access Policy compliant:

As of April 7 2008, the US NIH Public Access Policy requires that all peer reviewed articles resulting from research carried out with NIH funding be deposited in the Pubmed Central archive.

If you are an NIH employee or grantee Libertas Academica will ensure that you comply with the policy by depositing your paper at Pubmed Central on your behalf. 



 
 
 


Effect of Ribavirin Alone or Combined with Silymarin on Carbon Tetrachloride Induced Hepatic Damage in Rats

Authors: Omar M.E. Abdel Salam, Amany A. Sleem, Enayat A. Omara and Nabila S. Hassan
Publication Date: 14 Feb 2007
Drug Target Insights 2007:2 19-27

Omar M.E. Abdel Salam1, Amany A. Sleem1, Enayat A. Omara2 and Nabila S. Hassan2

1Department of Pharmacology, National Research Centre, Tahrir St., Dokki, Cairo, Egypt. 2Department of Pathology, National Research Centre, Tahrir St., Dokki, Cairo, Egypt.

Abstract: The effect of the antiviral agent ribavirin given alone or in combination with silymarin on the development of liver injury induced in rats with carbon tetrachloride (CCl4; 2.8 ml/kg followed by 1.4 ml/kg after one week) was studied. Ribavirin at three dose levels (30, 60 or 90 mg/kg), silymarin (25 mg/kg) or combination of ribavirin (60 mg/kg) and silymarin (25 mg/kg) was administered once daily orally for 14 days, starting at time of administration of CCl4. The administration of ribavirin decreased the elevations in serum alanine aminotransferase (ALT) by 78.5, 82.1, 75.1%, aspartate aminotransferase (AST) 47.5, 37.4, 38.8%, and alkaline phosphatase (ALP) by 23.4, 16, 21.6%, respectively and also prevented the development of hepatic necrosis caused by CCl4. In comparison, the elevated serum ALT, AST and ALP levels decreased to 43.3%, 46%, and 37.5% of controls, respectively by silymarin. When silymarin was combined with ribavirin, the serum activities of AST and ALP were further decreased, indicating a benefi cial additive effect. Morphometric analysis indicated signifi cant reduction in the area of necrosis and fi brosis on ribavirin treatment and this was further reduced after the addition of silymarin. Metabolic pertuberations caused by CCl4 as refl ected in a decrease in intracellular protein content in hepatocytes were improved by ribavirin monotherapy and to higher extent by combined silymarin and ribavirin therapy. Proliferating cell nuclear antigen was reduced in nuclei of hepatocytes by ribavirin montherapy or the combination of ribavirin and silymarin compared with CCl4-control group. The study demonstrates that ribavirin treatment in the model of CCl4- induced liver injury results in less liver damage. Results also indicate that the combined application of ribavirin and silymarin is likely to be a useful additive in reducing liver injury.

Categories: Pharmacology


Post comment




No comments yet...Be the first to comment.

Bookmark this article

LINKEDIN FACEBOOK

Add to Mixx! MIXX YAHOO! BUZZ

PERMALINK DIGG


Sign up for free journal updates

How should we address you?
Your email address
 Yes, sign up now


Recently published in this journal

A Model for NAD(P)H:Quinoneoxidoreductase 1 (NQO1) Targeted Individualized Cancer Chemotherapy
- 15/Jan/2009

The Toxicity of a Chemically Synthesized Peptide Derived from Non-Integrin Platelet Collagen Receptors
- 13/Aug/2008

The Target of 5-Lipoxygenase is a Novel Strategy over Human Urological Tumors than the Target of Cyclooxygenase-2
- 13/Jun/2008

Study of Alkylglycerol Containing Shark Liver Oil: a Physico Chemical Support for Biological Effect?
- 28/May/2008

Live Typhoid Vaccine for IBD-Patients—Well Tolerated and with Possible Therapeutic Effect
- 16/May/2008

Memantine: Reality and Potentiality
- 08/May/2008

Recent Advancements in Targeted Delivery of Therapeutic Molecules in Neurodegenerative Disease - Spinocerebellar Ataxia - Opportunities and Challenges
- 02/May/2008

The Beta3 499–513 Peptide Region is Required for AlphaIIb/ Beta3 Active Complex Formation and Fibrinogen Binding
- 28/Apr/2008

Therapies to Increase ApoA-I and HDL-Cholesterol Levels
- 23/Apr/2008

Use of Proteomics Analysis for Molecular Precision Approaches in Cancer Therapy
- 23/Apr/2008

Targeting Insulin-Like Growth Factor-1 Signaling into the Central Nervous System for Promoting Myelin Repair
- 18/Apr/2008

Thrombophilia
- 16/Apr/2008

Evidence of a Novel Gene from Aeromonas hydrophila Encoding a Putative Siderophore Receptor Involved in Bacterial Growth and Survival
- 18/Mar/2008

New-Onset Diabetes Mellitus Among Parkinsonian Patients Treated with Long-term Quetiapine
- 18/Mar/2008

Targeting Gallium to Cancer Cells through the Folate Receptor
- 01/Mar/2008

Targeted Brain Tumor Treatment: Current Perspectives
- 21/Jan/2008

Cytokine, Chemokine and Immune Activation Pathway Profiles in Celiac Disease: An Immune System Activity Screening by Expression Macroarrays
- 21/Jan/2008

Platelet-Derived Growth Factor as a Therapeutic Target for Systemic Autoimmune Diseases
- 11/Dec/2007

Effects of Ascorbic Acid, Alpha-Tocopherol and Allopurinol on Ischemia-Reperfusion Injury in Rabbit Skeletal Muscle: An Experimental Study
- 11/Dec/2007

Effect of live Salmonella Ty21a in Dextran Sulfate Sodium-induced Colitis
- 05/Nov/2007

Delivery Systems for In Vivo use of Nucleic Acid Drugs
- 14/Oct/2007

Use and Safety of Anthroposophic Medications for Acute Respiratory and Ear Infections: A Prospective Cohort Study
- 17/Sep/2007

Targeting Human Immunodeficiency Virus Type 1 Assembly, Maturation and Budding
- 17/Sep/2007

New Insights into the Understanding of Gastrointestinal Dysmotility
- 17/Sep/2007

Modulation of Visceral Nociception, Inflammation and Gastric Mucosal Injury by Cinnarizine
- 19/Jul/2007

Polymeric Nanoparticles, Nanospheres and Nanocapsules, for Cutaneous Applications
- 11/Jul/2007

Trypanothione Reductase: A Viable Chemotherapeutic Target for Antitrypanosomal and Antileishmanial Drug Design
- 19/Jun/2007

The Relationship of Arginine Deprivation, Argininosuccinate Synthetase and Cell Death in Melanoma
- 15/Jun/2007

The Adaptogens Rhodiola and Schizandra Modify the Response to Immobilization Stress in Rabbits by Suppressing the Increase of Phosphorylated Stress-activated Protein Kinase, Nitric Oxide and Cortisol
- 30/May/2007

Endothelial Dysfunction, Erectile Dysfunction and Phosphodiesterase 5 Inhibitors. An Update of the Current Data and Future Perspectives
- 29/May/2007

Circulating Vascular Endothelial Growth Factor (VEGF) Levels in Advanced Stage Cancer Patients Compared to Normal Controls and Diabetes Mellitus Patients with Critical Ischemia
- 18/May/2007

Phospholipase A2 Activates Hemostasis
- 22/Mar/2007

Targeting Receptors, Transporters and Site of Absorption to Improve Oral Drug Delivery
- 06/Mar/2007

Electrocardiographic Findings in Acutely and Chronically T. cruzi-infected Mice Treated by a Phenyl-Substituted Analogue of Furamidine DB569
- 05/Mar/2007

The Way that PEGyl-DSPC Liposomal Doxorubicin Particles Penetrate into Solid Tumor Tissue
- 28/Feb/2007

Modification of Monoaminergic Activity by MAO Inhibitors Influences Methamphetamine Actions
- 27/Feb/2007

Neurogenesis and The Effect of Antidepressants
- 26/Feb/2007

Inhibition of Intrinsic Thrombin Generation
- 25/Feb/2007

Neurogenesis and Alzheimer's Disease
- 24/Feb/2007

Accelerators of Osteogenesis by Recombinant Human Bone Morphogenetic Protein-2
- 21/Feb/2007

Long-term L-Carnitine Administration reduces Erythropoietin Resistance in Chronic Hemodialysis Patients with Thalassemia Minor
- 14/Feb/2007

Cyclophilin and Viruses: Cyclophilin as a Cofactor for Viral Infection and Possible Anti-Viral Target
- 14/Feb/2007

Effect of Ribavirin Alone or Combined with Silymarin on Carbon Tetrachloride Induced Hepatic Damage in Rats
- 14/Feb/2007



Related journals...